The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
General Updates | Treatment considerations with GPRC5D-targeted therapies in myeloma: optimizing sequencing
In this discussion, Sham Mailankody, MBBS, Memorial Sloan Kettering Cancer Center, New York, NY, and Jonathan Keats, PhD, Translational Genomics Research Institute, Phoenix, AZ, explore the growing complexity of sequencing therapies in multiple myeloma, particularly with expanding options such as CAR T-cells, bispecific antibodies, and targets including BCMA and GPRC5D. The experts emphasize the need for improved diagnostic tools to guide personalized treatment decisions and highlight strategies to determine the most effective therapy and modality for each patient, especially as resistance and antigen loss become more common. Additionally, Dr Mailankody and Dr Keats discuss evolving approaches, including bridging therapies, debulking prior to CAR-T, and the integration of genomic and immune profiling to improve outcomes and refine patient-specific care pathways.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
